156 related articles for article (PubMed ID: 19584820)
21. Reduced dose of lenograstim is as efficacious as standard dose of filgrastim for peripheral blood stem cell mobilization and transplantation: a randomized study in patients undergoing autologous peripheral stem cell transplantation.
Ataergin S; Arpaci F; Turan M; Solchaga L; Cetin T; Ozturk M; Ozet A; Komurcu S; Ozturk B
Am J Hematol; 2008 Aug; 83(8):644-8. PubMed ID: 18508321
[TBL] [Abstract][Full Text] [Related]
22. Mobilization strategies for the collection of peripheral blood progenitor cells: Results from a pilot study of delayed addition G-CSF following chemotherapy and review of the literature.
Jacoub JF; Suryadevara U; Pereyra V; Colón D; Fontelonga A; Mackintosh FR; Hall SW; Ascensão JL
Exp Hematol; 2006 Nov; 34(11):1443-50. PubMed ID: 17046563
[TBL] [Abstract][Full Text] [Related]
23. CD34+ cells mobilized by cyclophosphamide and granulocyte colony-stimulating factor (G-CSF) are functionally different from CD34+ cells mobilized by G-CSF.
Cesana C; Carlo-Stella C; Regazzi E; Garau D; Sammarelli G; Caramatti C; Tabilio A; Mangoni L; Rizzoli V
Bone Marrow Transplant; 1998 Mar; 21(6):561-8. PubMed ID: 9543059
[TBL] [Abstract][Full Text] [Related]
24. [Collection of hematopoietic progenitor cells from healthy donors].
Bojanić I; Cepulić BG; Mazić S
Acta Med Croatica; 2009 Jun; 63(3):237-44. PubMed ID: 19827352
[TBL] [Abstract][Full Text] [Related]
25. Cytoreduction of lymphoid malignancies and mobilization of blood hematopoietic progenitor cells with high doses of cyclophosphamide and etoposide plus filgrastim.
Damon L; Rugo H; Tolaney S; Navarro W; Martin T; Ries C; Case D; Ault K; Linker C
Biol Blood Marrow Transplant; 2006 Mar; 12(3):316-24. PubMed ID: 16503501
[TBL] [Abstract][Full Text] [Related]
26. A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products.
Lonial S; Hicks M; Rosenthal H; Langston A; Redei I; Torre C; Duenzl M; Feinstein B; Cherry J; Waller EK
Biol Blood Marrow Transplant; 2004 Dec; 10(12):848-57. PubMed ID: 15570253
[TBL] [Abstract][Full Text] [Related]
27. Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells.
Hicks ML; Lonial S; Langston A; Flowers C; Roback JD; Smith KJ; Mossavi Sai S; Teagarden D; Hamilton ES; Waller EK; Kaufman J
Transfusion; 2007 Apr; 47(4):629-35. PubMed ID: 17381621
[TBL] [Abstract][Full Text] [Related]
28. Mobilization of peripheral blood stem cells by granulocyte-colony stimulating factors: comparison of a standard dose of glycosylated and mutated granulocyte-colony stimulating factor in non-Hodgkin's lymphoma patients following CHOP therapy.
Takemoto Y; Wada H; Takatsuka H; Okamoto T; Kakishita E
Drugs Exp Clin Res; 2000; 26(1):1-5. PubMed ID: 10761530
[TBL] [Abstract][Full Text] [Related]
29. DCEP chemotherapy followed by a single, fixed dose of pegylated filgrastim allows adequate stem cell mobilization in multiple myeloma patients.
Zappasodi P; Nosari AM; Astori C; Ciapanna D; Bonfichi M; Varettoni M; Mangiacavalli S; Morra E; Lazzarino M; Corso A
Transfusion; 2008 May; 48(5):857-60. PubMed ID: 18248573
[TBL] [Abstract][Full Text] [Related]
30. A randomized comparison of once versus twice daily recombinant human granulocyte colony-stimulating factor (filgrastim) for stem cell mobilization in healthy donors for allogeneic transplantation.
Kröger N; Renges H; Krüger W; Gutensohn K; Löliger C; Carrero I; Cortes L; Zander AR
Br J Haematol; 2000 Dec; 111(3):761-5. PubMed ID: 11122135
[TBL] [Abstract][Full Text] [Related]
31. Flt3 ligand and thrombopoietin serum levels during peripheral blood stem cell mobilization with chemotherapy and recombinant human glycosylated granulocyte colony-stimulating factor (rhu-G-CSF, lenograstim) and after high-dose chemotherapy.
Bojko P; Pawloski D; Stellberg W; Schröder JK; Seeber S
Ann Hematol; 2002 Sep; 81(9):522-8. PubMed ID: 12373354
[TBL] [Abstract][Full Text] [Related]
32. The VAD chemotherapy regimen plus a G-CSF dose of 10 microg/kg is as effective and less toxic than high-dose cyclophosphamide plus a G-CSF dose of 5 microg/kg for progenitor cell mobilization: results from a monocentric study of 82 patients.
Lefrère F; Zohar S; Ghez D; Delarue R; Audat F; Suarez F; Hermine O; Damaj G; Maillard N; Ribeil JA; Azagury M; Misbahi R; Jondeau K; Cavazzana-Calvo M; Dal Cortivo L; Varet B
Bone Marrow Transplant; 2006 Apr; 37(8):725-9. PubMed ID: 16518433
[TBL] [Abstract][Full Text] [Related]
33. CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients.
Todisco E; Castagna L; Sarina B; Mazza R; Magagnoli M; Balzarotti M; Nozza A; Siracusano L; Timofeeva I; Anastasia A; Demarco M; Santoro A
Eur J Haematol; 2007 Feb; 78(2):111-6. PubMed ID: 17313558
[TBL] [Abstract][Full Text] [Related]
34. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E; Holte H; Pharo A; Kvaløy S; Jakobsen E; Smeland EB; Kvalheim G
Bone Marrow Transplant; 1998 May; 21(9):873-8. PubMed ID: 9613778
[TBL] [Abstract][Full Text] [Related]
35. ESHAP plus G-CSF as an effective peripheral blood progenitor cell mobilization regimen in pretreated non-Hodgkin's lymphoma: comparison with high-dose cyclophosphamide plus G-CSF.
Lee JL; Kim S; Kim SW; Kim EK; Kim SB; Kang YK; Lee J; Kim MW; Park CJ; Chi HS; Huh J; Kim SH; Suh C
Bone Marrow Transplant; 2005 Mar; 35(5):449-54. PubMed ID: 15654353
[TBL] [Abstract][Full Text] [Related]
36. Recombinant human granulocyte and granulocyte-macrophage colony-stimulating factor (G-CSF and GM-CSF) administered following cytotoxic chemotherapy have a similar ability to mobilize peripheral blood stem cells.
Hohaus S; Martin H; Wassmann B; Egerer G; Haus U; Färber L; Burger KJ; Goldschmidt H; Hoelzer D; Haas R
Bone Marrow Transplant; 1998 Oct; 22(7):625-30. PubMed ID: 9818688
[TBL] [Abstract][Full Text] [Related]
37. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH; Schwartzberg L; Li W; Hazelton B; West W
Bone Marrow Transplant; 1996 May; 17(5):715-21. PubMed ID: 8733687
[TBL] [Abstract][Full Text] [Related]
38. Increase of mobilized CD34-positive peripheral blood progenitor cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis.
Zeller W; Gutensohn K; Stockschläder M; Dierlamm J; Kröger N; Koehne G; Hummel K; Kabisch H; Weh HJ; Kühnl P; Hossfeld DK; Zander AR
Bone Marrow Transplant; 1996 May; 17(5):709-13. PubMed ID: 8733686
[TBL] [Abstract][Full Text] [Related]
39. Peripheral blood progenitor cell mobilization with intermediate-dose cyclophosphamide, sequential granulocyte-macrophage-colony-stimulating factor and granulocyte-colony-stimulating factor, and scheduled commencement of leukapheresis in 225 patients undergoing autologous transplantation.
Bashey A; Donohue M; Liu L; Medina B; Corringham S; Ihasz A; Carrier E; Castro JE; Holman PR; Xu R; Law P; Ball ED; Lane TA
Transfusion; 2007 Nov; 47(11):2153-60. PubMed ID: 17958545
[TBL] [Abstract][Full Text] [Related]
40. Biosimilar filgrastim (leucostim®) have similar efficacy in steady-state hematopoietic progenitor cell mobilization compared to original filgrastim (neupogen®) and lenograstim (granocyte®): A retrospective multicenter study.
Kayıkçı Ö; Tekgündüz E; Kaya AH; Göker H; Aslan A; İskender D; Namdaroglu S; Tetik A; Koçubaba Ş; Altuntaş F
Transfus Apher Sci; 2017 Dec; 56(6):832-835. PubMed ID: 29162397
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]